Increased Risk of Infusion Site Reactions with Fosaprepitant in Patients Receiving Anthracyclines
the Cancer Therapy Advisor take:
According to a new study published in the journal Anticancer Research, researchers have found that fosaprepitant, the intravenous formulation of the NK1 receptor antagonist aprepitant for the treatment of chemotherapy-induced nausea and vomiting, is associated with an increased risk of infusion site reactions in patients receiving anthracycline-based chemotherapy regimens compared with those receiving cisplatin-based regimens.
For the study, researchers sought to investigate the incidence of infusion site adverse effects in patients receiving different chemotherapy regimens. They retrospectively identified 267 patients who received either cisplatin- or anthracycline-based regimens.
Results showed that 41.7% of patients who received fosaprepitant experienced infusion site reactions compared with 10.9% of those who received aprepitant to prevent nausea and vomiting. Analyses showed no association between fosaprepitant and an elevated risk of infusion site adverse events in those receiving cisplatin-based regimens, but there was an assocation between the drug and an increased risk of infusion site adverse events among those who were administered anthracycline-based regimens (OR = 12.95; 95% CI: 5.74 - 29.20; P = 0.001).
The IV Emend prescribing information notes that infusion site reactions were experienced in 3% of patients that received fosaprepitant during clinical studies.
Fosaprepitant associated with increased risk of infusion site reactions in patients receiving anthracycline-based chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer